



ISSN (E): 2277- 7695

ISSN (P): 2349-8242

NAAS Rating: 5.03

TPI 2020; 9(4): 01-03

© 2020 TPI

www.thepharmajournal.com

Received: 01-02-2020

Accepted: 03-03-2020

T Rajeev Kumar

Asst Professor, Department of
Pharmaceutical Chemistry,
Southern Institute of Medical
Sciences, Guntur, Andhra
Pradesh, India

B Gopi Krishna

Doctor of Pharmacy, Southern
Institute of Medical Sciences,
Guntur, Andhra Pradesh, India

S Yashita Raga

Doctor of Pharmacy, Southern
Institute of Medical Sciences,
Guntur, Andhra Pradesh, India

SVS Gopi Raju

Doctor of Pharmacy, Southern
Institute of Medical Sciences,
Guntur, Andhra Pradesh, India

Syed. Fathima

Doctor of Pharmacy, Southern
Institute of Medical Sciences,
Guntur, Andhra Pradesh, India

G Radhika

Doctor of Pharmacy, Southern
Institute of Medical Sciences,
Guntur, Andhra Pradesh, India

Corresponding Author:**T Rajeev Kumar**

Asst Professor, Department of
Pharmaceutical Chemistry,
Southern Institute of Medical
Sciences, Guntur, Andhra
Pradesh, India

Simeprevir: A novice treatment option for chronic hepatitis C infection

T Rajeev Kumar, B Gopi Krishna, S Yashita Raga, SVS Gopi Raju, Syed Fathima and G Radhika

Abstract

Imeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) PI, has been recently approved for the treatment of genotype 1 chronic hepatitis C together with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is very effective and safe, with few adverse events. We discuss the precise features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, are going to be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be a part of future treatment strategies.


Keywords: Simeprevir, HIV-virus, evaluation studies

1. Introduction

Infection occurring because of hepatitis C virus (HCV) is a deadly reason many severe chronic liver disease, which can lead to progressive liver damage such as cirrhosis and hepatocellular carcinoma. It is counted as a great worldwide health problem mostly in Egypt, which has the greatest chance of the epidemic problem of HCV in the world in recorded by Egyptian Demographic Health Survey [EDHS] that had reached 14.7%. So prevention of HCV becomes a national priority [1].

The available medication chances for HCV infection until 2011 were confined to ribavirin with pegylated interferon combination. This drug mixture has calculated efficacy, mainly in genotype 1 infected patients, and was also having dangerous side effects [2].

In the year 2014, the directly acting antivirals were released in the market as a novel anti-HCV generation. The main intention of these novel drug therapies is reducing the incidence of possible side effects for HCV patients. These powerful drugs encompass Nonnucleoside Inhibitors (NNIs) and Nucleoside Inhibitors (NIs) of HCV RNA polymerase (NS5A/5B) and Protease Inhibitors [3].



The standard of separation depends on adsorption. When an assortment blend of mixes engaged with the mobile stage travels through a segment of the stationary stage they travel dependent on their relative affinities separately towards the stationary phase. The compound which has a greater affinity with respect to stationary phase ventures increasingly slow compound which has a lesser proclivity towards stationary stage travels quicker.

Henceforth the mixes are separated. No two mixes have a similar partiality for a mix of stationary phase, mobile phase and different conditions.

Drug Review

Giulio Nannettia, Silvana Pagnia, b, Saverio G. Parisia, b, Alfredo Albertia, Arianna Loregiana, b, 1, Giorgio Palù, b, 1 *et al.*, (2016)

A basic superior fluid chromatography strategy for the assurance of the hepatitis C infection protease inhibitor simeprevir in human plasma was created and approved. The technique included a fast and straightforward strong stage extraction of simeprevir utilizing Oasis HLB 1cc cartridges, isocratic turned around stage fluid chromatography on a XTerra RP18 (150 mm × 4.6 mm, 3.5 μm) section and bright identification at 225 nm. The mobile stage comprised of phosphate cushion (pH 6, 52.5 mM) and acetonitrile (30:70, v/v). This test ends up being delicate (lower point of confinement of measurement of 0.05 μg/mL), straight (connection coefficients ≥0.99), explicit (no obstruction with different possibly co-administrated drugs), reproducible (both intra-day and between-day coefficients of variety ≤8.3%), and precise (deviations went from -8.0 to 1.2% and from -3.3 to 6.0% for intra-day and between day examination, separately). The strategy was applied to remedial checking of patients experiencing simeprevir treatment for hepatitis C and end up being vigorous and dependable. Therefore, this strategy gives a straightforward, sensible, exact and reproducible measure for dosing simeprevir that can be promptly versatile to routine use by clinical research facilities with standard hardware.

Khalid A.M. Attia, Nasr M. El-Abasawi, Ahmed El-Olemy & Ahmed Serag *et al.*, (2017)

Simeprevir is a novel direct acting antiviral operator against hepatitis C infection. In the present work, a quick, explicit and reproducible reversible phase superior fluid chromatography with diode exhibit recognition (HPLC-DAD) strategy has been created and approved for the assurance of simeprevir within the sight of its constrained degradation products. The medication was exposed to variable pressure conditions including hydrolysis, oxidation, thermo and photolysis. The medication was seen as labile to acidic hydrolysis, essential hydrolysis, oxidation and photolysis yet stable in warm and nonpartisan hydrolytic conditions. Effective chromatographic detachment of simeprevir was accomplished on Discovery® HS C18 segment at a stream pace of 1 mL/min utilizing portable period of acetonitrile. The eluents were observed by the diode cluster indicator and pinnacle region esteems were estimated at 288 nm. The legitimacy of the strategy was surveyed by assessing exactness, accuracy, precision, and strength. The straight relapse examination information for the alignment bend shows a decent relationship in the scope of 1.5 - 45 μg/mL. The created strategy was effectively applied for the estimation of simeprevir in its commercial dose structure and could be utilized for the standard examination of the considered medication in quality control research centers.

B. Raj Kumar*1, Dr. K. V. Subrahmanyam 2 *et al.*, (2017) Simeprevir is impored in patients with hepatitis C virus (HCV) genotype 1 for the treatment of chronic hepatitis as a combination therapy, which liberates peg interferon alfa and ribavirin. Simeprevir is a protease inhibitor for HCV NS3/4A protease, which is needed for replication of the virus. A novel reversed phase high performance liquid chromatography (RP-HPLC) method has been vastly developed for the quantitative determination of Simeprevir and sobosuvir in pharma industry

and in Pharmaceutical dosage form by using symmetry X-Terra C18 as stationary phase and a mobile phase containing a mixture of Acetonitrile: Water (75:25% v/v). The flow rate was 1.0 ml/min and effluent was continually at 253nm and a peak eluted at .090, 5.289 ±0.02min and column oven temperature was maintained ambient. Calibration curve was plotted between the range of 0-30 μg/ml. The new RP-HPLC method was validated based on the current International Conference on Harmonization (ICH) guidelines for specificity, LOD, LOQ, linearity, accuracy, precision, intermediate precision and robustness. The results of the study reveals that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is helpful for the routine analysis of Simeprevir & Sofosbuvir in bulk drug and in many pharmaceutical dosage form.

Chenwei Pana, Yongping Chenb, Weilai Chenc, Guangyao Zhoua, Lingxiang Jina, Yi Zhenga, Wei Lina, , Zhenzhen Panb, *et al.*, (2016) In this work, a rapid and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the evaluation of ledipasvir, sofosbuvir and its metabolite GS-331007 in rat plasma was introduced. The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) by means of gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4 mL/min. The evaluation was done on a triple quadrupole tandem mass spectrometer by multi reaction monitoring (MRM) mode to regulates the precursor-to-product ion transitions of m/z 889.8 → 130.1 for ledipasvir, m/z 530.3 → 243.1 for sofosbuvir, m/z 261.5 → 113.1 for GS-331007 and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface. This method was validated over a concentration range of 2–500 ng/mL for ledipasvir, 10–2000 ng/mL for sofosbuvir and 10–2000 ng/mL for GS-331007. Actual time for each chromatography was 3.0 min. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels replicates relative standard deviations (RSD) < 10.2% and the accuracy values ranged from -9.8% to 11.2%. The method was successfully introduced to a pharmacokinetic study of ledipasvir, sofosbuvir and GS-331007 in rats.

Conclusion

In this present paper we had focused on the drug Simeprevir which can fight the virus Hepitis-C. Tremendous works on the stability, validation and determination of Simeprevir has reported my many of the researchers. determination of this drug by chromatographic methods are also repoted with low retention time.

References

1. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. *BMC Infectious Diseases*. 2013; 13(1-288) doi: 10.1186/1471-2334-13-288
2. Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma. 2016; 121:197-203.
3. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. *Clinical*

- Pharmacokinetics. 2015; 54(7):677-690. doi: 10.1007/s40262-015-0261-7
4. Stability-indicating HPLC-DAD Method for the Determination of Simeprevir. Journal Analytical Chemistry Letters 2017; 7:43-51 | Received 08 Dec 2016, Accepted 20 Jan 2017,1
 5. A New Validated Rp-Hplc Method for the Simultaneous Determination of Simeprevir and Sofosbuvir in Pharmaceutical Dosage Form. indo American journal of pharmaceutical research: ISSN NO 2231-6876 Mon, 2017
 6. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study. Journal of Chromatography B 2016; 1008:255-259.